drugset / Trial / NCT01721993

Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

NCT01721993

Phase 1 Completed 71 enrolled Thar Pharmaceuticals, Inc
Non-randomizedParallel-groupOpen-labelBasic science

Summary

THAR2011-1 is a Phase I, single dose, open-label dose-escalation study to determine the safety, absolute bioavailability, dose proportionality, and pharmacokinetics of T121 in healthy postmenopausal women. The study is expected to identify a safe dose that can be further tested in subsequent multiple dose studies comparing the safety, PK and pharmacodynamics (PD) of T121 with the currently marketed IV zoledronic acid (Zometa).

Timeline

Start
2013-01
Primary completion
2014-07
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject T121 Unknown
Comparator Zoledronic acid Other / unclassified Intravenous

Indications

No indication recorded.